Table 2 Per-cancer characteristics of low- and high-risk patients
From: The impact of pharmacokinetic gene profiles across human cancers
| Â | Low-risk cohort | High-risk cohort | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Age | Stage 1 or 2 | Stage 3 or 4 | Grade 1 or 2 | Grade 3 or 4 | N | Age | Stage 1 or 2 | Stage 3 or 4 | Grade 1 or 2 | Grade 3 or 4 | |
Any-Hit Model | ||||||||||||
 GBM | 125 | 62 ± 13.3 | – | – | – | – | 9 | 52 ± 23.7 | – | – | – | – |
 BRCA | 697 | 59 ± 13.3 | 533 | 164 | – | – | 118 | 53 ± 13.3 | 96 | 22 | – | – |
 OV | 159 | 58 ± 10.4 | 9 | 150 | 17 | 142 | 103 | 57 ± 13.3 | 10 | 93 | 19 | 84 |
 KIRC | 456 | 61 ± 13.3 | 389 | 67 | 211 | 245 | 14 | 58.5 ± 11.1 | 2 | 12 | 1 | 13 |
 LUAD | 319 | 67 ± 10.4 | 246 | 73 | – | – | 10 | 62.5 ± 12.6 | 6 | 4 | – | – |
 UCEC | 289 | 63 ± 10.4 | 226 | 63 | 164 | 125 | 44 | 61.5 ± 9.6 | 13 | 31 | 12 | 32 |
 HNSC | 287 | 61 ± 11.9 | 136 | 151 | 199 | 78 | 16 | 56.5 ± 10.4 | 14 | 2 | 11 | 5 |
 LUSC | 198 | 68.5 ± 8.2 | 152 | 46 | – | – | 14 | 65.5 ± 8.9 | 12 | 2 | – | – |
Therapy Efficacy Model | ||||||||||||
 GBM | 127 | 61 ± 13.3 | – | – | – | – | 7 | 52 ± 23.7 | – | – | – | – |
 BRCA | 776 | 58 ± 13.3 | 602 | 174 | 0 | 0 | 39 | 53 ± 13.3 | 27 | 12 | – | – |
 OV | 228 | 58 ± 11.1 | 16 | 212 | 31 | 197 | 34 | 60.5 ± 11.9 | 3 | 31 | 5 | 29 |
 KIRC | 463 | 61 ± 13.3 | 390 | 73 | 212 | 251 | 7 | 54 ± 8.9 | 1 | 6 | 0 | 7 |
 LUAD | 321 | 67 ± 10.4 | 247 | 74 | 0 | 0 | 8 | 67 ± 10.4 | 5 | 3 | – | – |
 UCEC | 310 | 63 ± 10.4 | 231 | 79 | 168 | 142 | 23 | 61 ± 10.4 | 8 | 15 | 8 | 15 |
 HNSC | 288 | 61 ± 11.9 | 137 | 151 | 200 | 78 | 15 | 57 ± 13.3 | 13 | 2 | 10 | 5 |
 LUSC | 202 | 68.5 ± 8.2 | 155 | 47 | 0 | 0 | 10 | 65 ± 8.9 | 9 | 1 | – | – |